Text Size

Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2005 by Melbourne Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Melbourne Health
ClinicalTrials.gov Identifier:
NCT00232219
First received: October 2, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted
  Purpose

The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion.

Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion.

Cardioversion involves resetting the heart back to normal with the use of electric current.

There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion.

Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.


Condition Intervention
Atrial Fibrillation
 Drug: Fish oil

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Official Title: Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.

Resource links provided by NLM:

Drug Information available for: Fish oil
U.S. FDA Resources

Further study details as provided by Melbourne Health:

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with persistent Atrial Fibrillation on Warfarin.

Exclusion Criteria:

  • paroxysmal atrial fibrillation with self terminating episodes.
  • left atrial size>6.0cm
  • myocardial infarction in the previous 6 months.
  • contraindications to amiodarone use .
  • cardiac surgery in the previous 3 months .
  • an acute reversible illness contributing to the development of af
  • a QTc interval > 480ms.
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00232219

Contacts
Contact: Paul Sparks, MBBS,PhD, FRACP 0393427000 ext 27133 paul.sparks@mh.org.au

Locations
Australia, Victoria
Royal Melbourne hospital Recruiting
Melbourne, Victoria, Australia, 3050
Contact: Paul Sparks, MBBS,PhD,FRACP     93427000 ext 27133     paul.sparks@mh.org.au    
Contact: Fiona Sutherland     93427000 ext 27133     fiona.sutherland@mh.org.au    
Sponsors and Collaborators
Melbourne Health
Investigators
Principal Investigator: Paul Sparks, MBBS, PhD. FRACP Melbourne Health
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00232219     History of Changes
Other Study ID Numbers: 2003.188
Study First Received: October 2, 2005
Last Updated: October 2, 2005
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Additional relevant MeSH terms:
Atrial Fibrillation
Recurrence
Arrhythmias, Cardiac
Heart Diseases
 Cardiovascular Diseases
Pathologic Processes
Disease Attributes

ClinicalTrials.gov processed this record on May 19, 2013